Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 11, 1997

View Archived Issues

Spiro compounds for CNS disorders disclosed by Takeda

U.S. and European investigators describe agents for CNS disorders

ET antagonists reported by Japanese investigators

Takeda prepares NO production inhibitors

Sankyo develops antidiabetic agents

Eisai synthesizes heterocyclic anticancer compounds

Hypoglycemic/hypolipidemic agents from Kyorin

Sumitomo develops ACAT inhibitors

Diagnostic MAbs from Terumo

Update on GEM-91

Potent gpIIb/IIIa antagonist synthesized using combinatorial techniques

U.S. patent issued for meningococcal B vaccine

Selective gelatinase inhibitor described by British Biotech

Tanabe selects ellipticine derivative for further development

Potent dual CCK-A/CCK-B antagonist discovered by Japanese researchers

Genzyme Transgenics reports advances in transgenic production of MAbs

Merck & Co. and Costa Rican institute renew biological diversity agreement

U.S. researchers report significant advance in gene therapy for hearing disorders

ChemTrak colorectal cancer home test ready for launch

Essential fatty acids in schizophrenia

Cangene awarded ISO registration

Remune associated with chemokine induction

U.K. launch for SKB anticancer treatment

Positive phase III trials results for citicoline

Tretinoin gel cleared for marketing by FDA

T Cell Sciences awarded second grant for vaccine development

Sparta expands clinical trials of retinoid

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...